PD-L1 Blockade for Cancer Treatment: MEDI4736

Seminars in Oncology

Volumn 42, Issue 3, 2015, Pages 474-483

  Ibrahim, Ramy ^a   Stewart, Ross ^b   Shalabi, Aiman ^a  

^a ASTRAZENECA   (United Kingdom)

^b MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; PROGRAMMED DEATH 1 LIGAND 1; TICILIMUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CLINICAL ASSESSMENT; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG MECHANISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; INTERMETHOD COMPARISON; JAPANESE (PEOPLE); MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYELODYSPLASTIC SYNDROME; NON SMALL CELL LUNG CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REGISTRATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM; NEOPLASMS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS;

EID: 84929208764     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.02.007     Document Type: Review

References (40)

1. M. Tosolini, A. Kirilovsky, and B. Mlecnik Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer Cancer Res 71 2011 1263 1271
2. J. Hamanishi, M. Mandai, and K. Abiko The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors Clin Immunol 141 2011 338 347
3. J. Galon, H.K. Angell, D. Bedognetti, and F.M. Marincola The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures Immunity 39 2013 11 26
4. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 2008 677 704
5. J.J. Park, R. Omiya, and Y. Matsumura B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance Blood 116 2010 1291 1298
6. W. Zou, and L. Chen Inhibitory B7-family molecules in the tumor microenvironment Nat Rev Immunol 8 2008 467 477
7. D.F. McDermott, and M.B. Atkins PD-1 as a potential target in cancer therapy Cancer Med 2 2013 662 673
8. C.Y. Mu, J.A. Huang, Y. Chen, C. Chen, and X.G. Zhang High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation Med Oncol 28 2011 682 688
9. L. Wang, Q. Ma, X. Chen, K. Guo, J. Li, and M. Zhang Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma World J Surg 34 2010 1059 1065
10. J. Hamanishi, M. Mandai, and M. Iwasaki Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 104 2007 3360 3365
11. J.R. Brahmer, S.S. Tykodi, and L.Q. Chow Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
12. M. Sznol, and L. Chen Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer Clin Cancer Res 19 2013 1021 1034
13. R.A. Stewart, M. Morrow, and M. Chodorge MEDI4736: Delivering effective blockade of immunosuppression to enhance tumour rejection: Monoclonal antibody discovery and preclinical development [abstract] Cancer Res 71 8 Suppl 2011 $58#[#,63]?>abstract LB-158
14. D. Fairman, R. Narwal, and M. Liang Pharmacokinetics of MEDI4736, a fully human anti-PDL1 monoclonal antibody, in patients with advanced solid tumors. Poster presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 30 June 03, 2014 J Clin Oncol (Meeting Abstracts) 32 2014 abstract 2602
15. J. Lutzky, S. Antonia, and S.N. Khleif A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. Slides presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 30 June 03, 2014 J Clin Oncol (Meeting Abstracts) 32 2014 abstract 3001
16. N.H. Segal, S.J. Antonia, and J.R. Brahmer Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Slides presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 30 June 03, 2014 J Clin Oncol (Meeting Abstracts) 32 2014 abstract 3002
17. J.R. Brahmer, N.A. Rizvi, and J. Lutzky Clinical activity and biomarkers of MEDI4736, an anti-PDL1 antibody, in patients with NSCLC. Poster presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 30 June 03, 2014 J Clin Oncol (Meeting Abstracts) 32 2014 $58#[#,63]?>abstract 8021
18. N.H. Segal, O. Hamid, and W.J. Hwu A phase 1 multi-arm dose-expansion study of the anti-programmed cell death-ligand-1 (PD-L1) antibody MEDI4736: preliminary data. Poster presented at the European Society for Medical Oncology (ESMO) Annual Meeting, Madrid, Spain, September 26-30, 2014 Ann Oncol 25 suppl 4 2014:[#,63]?>iv365 (1058PD)
19. S. Antonia, S.-H. Ou, and S.N. Khleif Clinical activity and safety of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with NSCLC. Poster presented at the European Society for Medical Oncology (ESMO) Annual Meeting, Madrid, Spain, September 26-30, 2014 Ann Oncol 25 suppl 4 2014 $58#[#,63]?>iv466 (1325P)
20. M. Fury, M. Butler, and S.-H. Ou Clinical activity and safety of MEDI4736, an anti-PD-L1 antibody, in patients with head and neck cancer. Poster presented at the European Society for Medical Oncology (ESMO) Annual Meeting, Madrid, Spain, September 26-30, 2014 Ann Oncol 25 suppl 4 2014:[#,63]?>iv341 (988PD)
21. R. Stewart, K. Mulgrew, and S. Wang Blockade of PD-L1 mediated immunosuppression for cancer therapy - MEDI4736 monoclonal antibody discovery and preclinical development. Slides presented at the 27th Annual Scientific Meeting of the Society for Immunotherapy of Cancer (SITC), North Bethesda, MD, USA, October 26-28, 2012 J Immunother Cancer (Meeting Abstracts) 35 9 2012 765 766
22. S.N. Khleif, J. Lutzky, and N. Segal MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumors. Slides presented at the European Cancer Congress (ECC), Amsterdam, Netherlands, September 27 October 1, 2013 Eur J Cancer (Meeting Abstracts) 49 suppl 2 2013 $58#[#,63]?>abstract 802
23. V. Oganesyan, C. Gao, L. Shirinian, H. Wu, and W.F. Dall'Acqua Structural characterization of a human Fc fragment engineered for lack of effector functions Acta Crystallogr D Biol Crystallogr 64 2008 700 704
24. R. Stewart, S. Mullins, and A. Watkins Preclinical modelling of immune checkpoint blockade. Poster presented at the American Association of Immunologists (AAI) Annual Meeting, Honolulu, HI, USA, May 03 07, 2013 J Immunol 190 2013 abstract 214.7 (P2012)
25. S.J. Dovedi, A.L. Adlard, and G. Lipowska-Bhalla Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade Cancer Res 74 19 2014 5458 5468
26. A. Ribas, L.H. Camacho, and G. Lopez-Berestein Anti-tumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206 J Clin Oncol 35 2005 8968 8977
27. M. Vanneman, and G. Dranoff Combining immunotherapy and targeted therapies in cancer treatment Nat Rev Cancer 12 2012 237 251
28. I. Melero, A.M. Grimaldi, J.L. Perez-Gracia, and P.A. Ascierto Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination Clin Cancer Res 19 2013 997 1008
29. D.M. Pardoll The blockade of immune checkpoints in cancer immunotherapy Nat Rev Cancer 12 2012 252 264
30. ClinicalTrials.gov. https://clinicaltrials.gov (accessed January 2015).
31. N.A. Rizvi, J.E. Gray, M. Ballas, D. Jayawardene, P.K. Stockman, and J.D. Powderly A phase 2, non-comparative, open-label, international study of MEDI4736 in patients with locally advanced or metastatic PD-L1-positive NSCLC (stage 3B-4) who have received≥2 prior systemic treatment regimens (ATLANTIC). Poster presented at the European Society for Medical Oncology Annual Meeting (ESMO), Madrid, Spain, September 26-30, 2014 Ann Oncol 25 suppl 4 2014 $58#[#,63]?>iv470 (1335TiP)
32. S.J. Antonia, N.O. Iannotti, and M.A. Salamat A phase 3, randomised, double-blind, placebo-controlled, international study of MEDI4736 in patients with locally advanced, unresectable NSCLC (stage III) who have not progressed following platinum-based, concurrent chemoradiation therapy (PACIFIC). Poster presented at the European Society for Medical Oncology (ESMO) Symposium on Immuno-Oncology, Geneva, Switzerland, November 21-22, 2014 Ann Oncol 25 suppl 6 2014 $58#[#,63]?>vi6 (16TiP)
33. L. Deng, H. Liang, and B. Burnette Irradiation and anti-PD-L1 treatment synergistically promote anti-tumor immunity in mice J Clin Invest 124 2014 687 695
34. P. Zhang, D.M. Su, M. Liang, and J. Fu Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosis Mol Immunol 45 2008 1470 1476
35. M.C. Pinder, N.A. Rizvi, and S.B. Goldberg A Phase 1b open-label study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in subjects with advanced non-small cell lung cancer [abstract] J Clin Oncol (Meeting Abstracts) 2014 32 abstract e19137
36. S. Antonia, S. Goldberg, and A. Balmanoukian A phase I open-label study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death-ligand 1(PD-L1) antibody, in combination with tremelimumab in patients with advanced non-small cell lung cancer (NSCLC). Poster presented at the European Society for Medical Oncology Annual Meeting (ESMO), Madrid, Spain, September 26 30, 2014 Ann Oncol 25 suppl 4 2014 iv466 iv467 (1327P)
37. D.A. Cross, S.E. Ashton, and S. Ghiorghiu AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer Cancer Discov 4 2014 1046 1061
38. R.G. Petit, and P. Basu ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer [abstract] J Immunother Cancer 1 Suppl 1 2013 P231
39. M.K. Callahan, P.A. Ott, and K. Odunsi A phase I study to evaluate the safety and tolerability of MEDI4736, an anti-PD-L1 antibody, in combination with tremelimumab in patients with advanced solid tumors. Poster presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 30 June 03, 2014 J Clin Oncol (Meeting Abstracts) 32 2014 abstract TPS3120
40. M. Gordon, J. Lutzky, and D. Lawrence Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma. Poster presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 30 June 03, 2014 J Clin Oncol (Meeting Abstracts) 32 2014 abstract TPS9108